Cannabidiol to remain a controlled drug: here’s what is changing

By   /   August 9, 2017  /   3 Comments

TDB recommends Voyager - Unlimited internet @home as fast as you can get

Rather than basing our approach on synthetic pharmaceuticals, if we took a herbal remedy or food-grade approach, then local and affordable cannabis-based products could be available here within months. They could be made from hemp, they would be cheap, local workers would be employed making them, and everyone could get their daily dose of phyto-cannabinoids. 

Associate Health Minister Peter Dunne has announced Cannabidiol (CBD) will remain a controlled drug with restrictions expected to be lifted in September so that GPs and other doctors can prescribe CBD to patients without needing special approval.

Dunne’s changes will help some patients – eventually – but a lot more could be done.

CBD will remain a controlled drug, just easier to prescribe.

Doctors will be able to prescribe approved CBD products or unapproved products manufactured overseas. But it won’t be easy. There are currently no approved products, registration is difficult, no products can be made in NZ, and funding will remain an issue for many patients.

CBD is a non-psychoactive cannabinoid found in cannabis plants that is indicated to help patients wide a variety of conditions including epilepsy, arthritis, cardiovascular disease, cancer, diabetes, gastrointestinal disorders, multiple sclerosis, PTSD, antibiotic-resistant infections, anxiety and other mental health disorders, and more. CBD can be made from legal hemp crops, and is available in many countries.

Despite not being listed in the Misuse of Drugs Act, the NZ Ministry of Health says cannabidiol is a Class B1 controlled drug that has required special Ministerial approval under the 1977 Misuse of Drugs regulations.

The Government’s intention is to pharmaceuticalise CBD, rather than let patients or caregivers grow their own CBD-rich herbal cannabis, or make it locally from hemp.

Patients with prescriptions will be able to buy their own from overseas and have up to three month’s supply sent to New Zealand, or they can have their prescription filled locally if their prescriber, pharmacy or a pharmaceutical company brings it in for them (controlled drugs are not allowed to be stockpiled).

Peter Dunne says the changes are “the culmination of a process which I began early this year after receiving independent advice from the Expert Advisory Committee on Drugs”.

Well, that was itself a result of Nelson lawyer Sue Grey’s threat of legal action against the Ministry of Health, and the subsequent fast-tracking of a clinical trial that showed medical benefits from using CBD in children with epilepsy.

It’s good there will be a 2% tolerance for trace amounts of other cannabinoids, as this means that botanically-sourced (ie, natural) cannabis can be used rather than having to make synthetic CBD in a lab.

However it will remain very difficult to register products made from cannabis plants. Controlled drugs can only be manufactured here for research or study, not commercial purposes. Registering an approved product requires clinical trials, which could take years, and can only be conducted using GMP certified cannabis. Importing or distributing medical cannabis products requires permits which can only be obtained by research institutions or pharmaceutical companies.

Unapproved products will also need to be GMP-grade, or the prescribing doctor can expect close and ongoing scrutiny. For many doctors it will be too hard and too risky for them to prescribe unapproved products.

Funding will also remain an issue, with any pharma-CBD products expected to be expensive like Sativex. This would put it out of reach for many patients, especially compared to growing their own, or making it from hemp.

Rather than basing our approach on synthetic pharmaceuticals, if we took a herbal remedy or food-grade approach, then local and affordable cannabis-based products could be available here within months. They could be made from hemp, they would be cheap, local workers would be employed making them, and everyone could get their daily dose of phyto-cannabinoids.

***
Want to support this work? Donate today
***
Follow us on Twitter & Facebook
***

About the author

Chris Fowlie

Former editor of NORML News, Chris Fowlie is president of the National Organisation for the Reform of Marijuana Laws, manager of The Hempstore, and court-recognised expert witness for serious cannabis charges.

3 Comments

  1. I can attest to the cost issue. A “near pharmaceutical” product from Canada, pure CBD, is predicted to cost up to 100k per year to treat a child for Epilepsy. This is based on max doses used in australia of 25mg of CBD per KG of bodyweight, and the teen weighing 50kg now.

    This teen has had 2 brain surgeries, and deserves a shot.
    The cost is the only reason we haven’t had success at MCANZ.
    Instead we are refocusing on a high THC product and hope to get local storage for timely supply in palliative care by early 2018.

    Additionally these “near pharmaceuticals” will need a heavy education element with doctors, if we trade dosing accuracy from 5% to 10% it can halve the cost of the end product. There is more clinical benefit in affording the product than a minor quibble over dosing accuracy.

    In summary, there is a near pharma grade CBD product available before years end, good luck being able to afford it though! this declassification is literally taunting to parents with high needs children.

  2. Danyl Strype says:

    Dunne wants to look like he’s learned from his failure to help Alex Renton, who might still be alive today if Dunne hadn’t blocked cannabis law reform when he joined Helen Clark’s government in 1999. All this weak, toddling reform shows is that he (and the NatACT government he’s part of) have learned nothing, or that they just don’t care if their shilling for the corporate pharmaceutical industry costs lives. I’m crossing my fingers that this election, someone will finally flush the Dunney.

  3. […] This post was originally published on The Daily Blog, 9 August 2017 […]